VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2014

Nov 7, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2014-11-05

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-11-05	Common Stock	M	4250	$45.11	Acquired	121514	Direct
2014-11-05	Common Stock	S	2576	$112.07	Disposed	118938	Direct
2014-11-05	Common Stock	S	1374	$112.98	Disposed	117564	Direct
2014-11-05	Common Stock	S	300	$113.98	Disposed	117264	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-11-05	Stock Option (right to buy)	$45.11	M	4250	Disposed	2023-02-04	Common Stock (4250)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $112.07 (range $111.54 to $112.53).

F4: Open market sales reported on this line occurred at a weighted average price of $112.98 (range $112.60 to $113.46).

F5: Open market sales reported on this line occurred at a weighted average price of $113.98 (range $113.67 to $114.29).

F6: The option vests in 16 quarterly installments from 02/05/2013.